Category - Markets

Markets

Stifel starts 3 NASH companies at buy; 3 at hold

In a new industry report on the future of NASH (nonalcoholic steatohepatitis), Stifel launched coverage of six NASH companies, with three “buy” and three “hold” recommendations.

June 25, 2019

Markets

WB cuts Acer Therapeutics to MP from OP

William Blair downgraded Acer Therapeutics (NASDAQ:ACER) to “market perform” from “outperform” after the company received a complete response letter from the FDA for its lead product, Edsivo (celiprolol).

June 25, 2019

Markets

HCW starts Medivir at buy; PT 54 Swedish krona (SEK)

H.C. Wainwright initiated coverage of Medivir (NASDAQ, Stockholm:MVIR) with a “buy” rating and price target of SEK 54. The stock closed at SEK 22.55 on June 24.

June 25, 2019

Markets

HCW ups Krystal Biotech PT to $56 from $38

H.C. Wainwright raised its price target for Krystal Biotech (NASDAQ:KRYS) to $56 from $38 after the company posted positive results from its GEM-2 study, a Phase 2 clinical trial of KB103 in patients with recessive...

June 24, 2019

Markets

Ladenburg ups Palatin Technologies PT to $3.75 from $2.75

Ladenburg Thalmann raised its price target for Palatin Technologies (NYSE American:PTN) to $3,75 from $2.75 after the FDA approved Vyleesi as the first as-needed treatment of premenopausal women with acquired...

June 24, 2019

Markets

Stifel cuts AnaptysBio to hold; PT to $74 from $124

Stifel downgraded AnaptysBio (NASDAQ:ANAB) to “hold” from “buy” and cut its price target to $74 from $124 after disappointing clinical results from a competing asthma drug.

June 21, 2019

Markets

HCW starts Iterum Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Iterum Therapeutics (NASDAQ:ITRM) with a “buy” rating and $17 price target. The stock closed at $6.60 on June 20.

June 21, 2019

Markets

SVB Leerink starts Axovant Gene Therapies at OP; PY $18

SVB Leerink initiated coverage of Axovant Gene Therapies (NASDAQ:AXGT) with an “outperform” rating and $18 price target. The stock closed at $5.79 on June 20.

June 21, 2019

Markets

BTIG cuts Verastem to Neutral; PT removed

BTIF downgraded Verastem (NASDAQ:VSTM) to “neutral” from “buy” and removed its previous price target of $8 after the company announced that president and CEO, Robert Forrester, was stepping down. The stock closed at $1...

June 20, 2019

Markets

Alliance Global starts Precipio at buy; PT $6.30

Alliance Global Partners launched coverage of Precipio (NASDAQ:PRPO) with a “buy” rating and price target of $6.30. The stock closed at $3.12 on June 19.

June 20, 2019

Category - Markets

Subscribe